Peptic Ulcer Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Peptic Ulcer Disease

MalaCards integrated aliases for Peptic Ulcer Disease:

Name: Peptic Ulcer Disease 12 15
Peptic Ulcer 37 29 55 43 44 72
Acute Peptic Ulcer Without Hemorrhage and Without Perforation 12
Acute Peptic Ulcer with Hemorrhage and Perforation 12
Acute Peptic Ulcer with Hemorrhage 12


External Ids:

Disease Ontology 12 DOID:750
KEGG 37 H01634
ICD9CM 35 533
MeSH 44 D010437
NCIt 50 C3318
SNOMED-CT 68 13200003
ICD10 33 K27
UMLS 72 C0030920

Summaries for Peptic Ulcer Disease

MedlinePlus : 43 A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse. To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Peptic Ulcer Disease, also known as peptic ulcer, is related to active peptic ulcer disease and zollinger-ellison syndrome, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Peptic Ulcer Disease is HRH2 (Histamine Receptor H2), and among its related pathways/superpathways are NF-kappaB Signaling and Selenium Micronutrient Network. The drugs Acetylcysteine and Enalapril have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and colon, and related phenotypes are digestive/alimentary and homeostasis/metabolism

KEGG : 37
Peptic ulcer is a common disorder of gastrointestinal system characterized by mucosal damage secondary to pepsin and gastric acid secretion. It usually occurs in the stomach and proximal duodenum. Typical symptoms include episodic burning epigastric pain, loss of appetite, and weight loss. Pain usually occurs two to five hours after meals or on an empty stomach. The most common causes of peptic ulcer are Helicobacter pylori infection and use of nonsteroidal anti-inflammatory drugs (NSAIDs). Smoking increases the risk of ulcer recurrence and slows healing. Most patients are treated successfully with eradication of H. pylori and/or avoidance of NSAIDs, along with the appropriate use of antisecretory therapy. About 25 percent of patients with peptic ulcer have a serious complication such as hemorrhage, perforation, or gastric outlet obstruction. Administration of proton pump inhibitors (PPIs) and endoscopic therapy control most bleeds.

Wikipedia : 75 Peptic ulcer disease (PUD) is a break in the inner lining of the stomach, first part of the small... more...

Related Diseases for Peptic Ulcer Disease

Diseases related to Peptic Ulcer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 646)
# Related Disease Score Top Affiliating Genes
1 active peptic ulcer disease 33.9 PTGS2 PTGS1 HRH2 ATP4A
2 zollinger-ellison syndrome 32.3 SCT MEN1 HRH2 GAST
3 multiple endocrine neoplasia, type i 31.9 SCT MEN1 GAST
4 duodenitis 31.7 GAST ATP4A
5 helicobacter pylori infection 31.5 S100A8 IL1B GAST CYP2C19 CXCL8
6 peptic ulcer perforation 31.0 S100A8 PTGS2 HRH2 GAST ATP4A
7 bile reflux 31.0 PTGS2 ATP4A
8 aspiration pneumonitis 30.9 HRH2 ATP4A
9 opisthorchiasis 30.9 TNF IL1B CXCL8
10 esophagitis 30.6 PTGS2 IL1B HRH2 CYP2C19 CXCL8
11 pylorospasm 30.5 GHRL GAST
12 dyspepsia 30.4 PTGS2 PTGS1 HRH2 GHRL CYP2C19 CXCL8
13 peptic esophagitis 30.4 IL1B HRH2 CYP2C19 CXCL8 ATP4A
14 stomach disease 30.3 S100A8 PTGS2 PTGS1 IL1B HRH2 GHRL
15 aspirin resistance 30.3 PTGS2 PTGS1
16 gastrinoma 30.2 SCT MEN1 GAST
17 lung disease 30.2 TNF IL1B IL10 CXCL8
18 cytomegalovirus infection 30.2 TNF IL1B CXCL8
19 cystitis 30.2 TNF PTGS2 CXCL8
20 tonsillitis 30.2 TNF IL1B CXCL8
21 crohn's disease 30.1 TNF S100A8 IL10
22 endocarditis 30.1 TNF IL10 CXCL8
23 peritonitis 30.1 TNF IL1B IL10 CXCL8
24 fatty liver disease 30.1 TNF IL1B CXCL8
25 gastroenteritis 30.0 TNF IL1B IL10 CXCL8
26 pancreas disease 30.0 TNF SCT GAST
27 pericarditis 30.0 TNF IL1RN IL1B
28 alcoholic hepatitis 30.0 TNF IL10 CXCL8
29 gastritis 29.9 S100A8 PTGS2 IL1RN IL1B HRH2 GHRL
30 hernia, hiatus 29.9 CYP2C19 ATP4A
31 autoimmune gastritis 29.9 TNF IL1B IL10
32 scrub typhus 29.9 TNF IL1B IL10
33 gastric ulcer 29.8 PTGS2 PTGS1 IL1RN IL1B HRH2 GAST
34 bacterial infectious disease 29.8 TNF IL1B IL10 CXCL8
35 ulcerative colitis 29.8 TNF IL1B IL10 CXCL8
36 idiopathic achalasia 29.7 TNF IL10
37 silicosis 29.7 TNF IL1RN IL1B CXCL8
38 periodontitis 29.6 TNF IL1B IL10 CXCL8
39 pneumoconiosis 29.6 TNF IL1B CXCL8 CAT
40 appendicitis 29.6 TNF IL1B IL10 CXCL8
41 sleep apnea 29.6 TNF IL1B GHRL CXCL8
42 toxic shock syndrome 29.6 TNF IL1B IL10 CXCL8
43 inflammatory bowel disease 29.5 TNF IL1B IL10 CXCL8
44 gastric adenocarcinoma 29.5 TNF S100A8 PTGS2 IL1RN IL1B GAST
45 acute pancreatitis 29.5 SCT IL10 CXCL8
46 pneumonia 29.5 TNF IL1B IL10 CXCL8
47 brucellosis 29.4 TNF IL1RN IL10 CXCL8
48 arthritis 29.3 TNF PTGS2 IL1RN IL1B IL10 CXCL8
49 atrophic gastritis 29.2 TNF S100A8 IL1RN IL1B GHRL GAST
50 colitis 29.2 TNF PTGS2 IL1B IL10 CXCL8

Comorbidity relations with Peptic Ulcer Disease via Phenotypic Disease Network (PDN):

Acute Cystitis

Graphical network of the top 20 diseases related to Peptic Ulcer Disease:

Diseases related to Peptic Ulcer Disease

Symptoms & Phenotypes for Peptic Ulcer Disease

UMLS symptoms related to Peptic Ulcer Disease:

nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, signs and symptoms, digestive, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Peptic Ulcer Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.97 ATP4A GAST GHRL HRH2 IL10 MEN1
2 homeostasis/metabolism MP:0005376 9.93 ATP4A CAT GAST GHRL HRH2 IL10
3 endocrine/exocrine gland MP:0005379 9.91 ATP4A GAST GHRL HRH2 IL10 MEN1
4 mortality/aging MP:0010768 9.7 ATP4A CAT GAST IL10 IL1B IL1RN
5 neoplasm MP:0002006 9.28 ATP4A CAT GAST IL10 IL1B MEN1

Drugs & Therapeutics for Peptic Ulcer Disease

Drugs for Peptic Ulcer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 340)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
Enalaprilat Approved Phase 4 76420-72-9 6917719
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Coal tar Approved Phase 4 8007-45-2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Atorvastatin Approved Phase 4 134523-00-5 60823
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
17 Orange Approved Phase 4
Ticagrelor Approved Phase 4 274693-27-5 9871419
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Bisoprolol Approved Phase 4 66722-44-9 2405
Thrombin Approved, Investigational Phase 4
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
Phylloquinone Approved, Investigational Phase 4 84-80-0
Dalteparin Approved Phase 4 9005-49-6
26 Bemiparin Approved, Investigational Phase 4 91449-79-5
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
Misoprostol Approved Phase 4 59122-46-2 5282381
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Ibuprofen Approved Phase 4 15687-27-1 3672
Clarithromycin Approved Phase 4 81103-11-9 84029
Ofloxacin Approved Phase 4 82419-36-1 4583
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Famotidine Approved Phase 4 76824-35-6 3325
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271

Interventional clinical trials:

(show top 50) (show all 324)
# Name Status NCT ID Phase Drugs
1 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
2 Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding Unknown status NCT00687336 Phase 4
3 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
4 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
5 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
6 Oral vs Intravenous Proton Pump Inhibitor(PPI) in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial Unknown status NCT01123031 Phase 4 lansoprazole;esomeprazole
7 Compare Gastric Acid Suppression of Esomeprazole by Oral or Intravenous Administration - A Randomized Trial Unknown status NCT00471029 Phase 4 esomeprazole
8 A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding Unknown status NCT01275937 Phase 4 Esomeprazole;esomeprazole
9 Aspirin and the Antiproteinuric Effect of Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients: a Randomized, Double-Blind, Placebo-Controlled Study Unknown status NCT00427271 Phase 4 aspirin
10 "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" Unknown status NCT02028234 Phase 4 Pantoprazole,;Omeprazole
11 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
12 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
13 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
14 Optimal Anti-Platelet Treatment for Patients With Stent IMplantation And Clopidogrel Low Response: OPTIMAL Study Unknown status NCT01955200 Phase 4 Ticagrelor;Clopidogrel;Cilostazol;Clopidogrel;Clopidogrel
15 A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease Completed NCT00534443 Phase 4
16 Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial Completed NCT01418300 Phase 4 sequential versus triple
17 Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial Completed NCT01180179 Phase 4 Lansoprazole;Famotidine
18 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
19 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
20 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
21 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
22 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
23 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
24 Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication Completed NCT02175901 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Amoxicillin;Metronidazole;Clarithromycin
25 Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study Completed NCT01896557 Phase 4 omeprazole;Ranitidine;Clopidogrel
26 Proton Pump Inhibitor Treatment Stop: Discontinuation of Acid-suppressive Medication Among Long-term Users in a Primary Health Care Setting Completed NCT00120315 Phase 4 esomeprazole
27 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
28 Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
29 Phase 4 Study of Intravenous Proton Pump Inhibitor in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial Completed NCT00731601 Phase 4 pantoprazole;pantoprazole
30 The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease Completed NCT00354757 Phase 4 rabeprazole
31 The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy Completed NCT00840008 Phase 4
32 Comparison of Twq Different Regimen of Vaginal Misoprostol for Nid Trimester MTP Completed NCT00401440 Phase 4 Misoprostol;Misoprostol
33 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
34 The Therapeutic Role of Albumin Supply on Peptic Ulcer Bleeding and the Correlation Between Clinical Course and Expression of Serum Response Factor on Ulcer Tissue and Superoxide Free Radical in Blood Completed NCT01822600 Phase 4 Human albumin;Omeprazole
35 Famotidine vs. Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion - a Randomized Controlled Study Completed NCT00843063 Phase 4 pantoprazole vs famotidine
36 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers Completed NCT01353144 Phase 4 aspirin
37 The Feasibility of Fast-track Surgery for Perforated Peptic Ulcers. A Prospective Randomized Clinical Trial Completed NCT01620671 Phase 4
38 A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection Completed NCT02092506 Phase 4 10 day triple therapy;10 day sequential therapy;10 day concomitant therapy
39 Comparison of Efficiency of High Dose Atorvastatin and Endothelial Progenitor-Capture Stents and Bare Metal Stents in Reduction of Neointimal Formation in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Completed NCT00494247 Phase 4
40 The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients Completed NCT02648659 Phase 4 Ilaprazole;Amoxicillin;Clarithromycin;Metronidazole
41 Eradication of Helicobacter Pylori According to 23S rRNA Point Mutations Associated With Clarithromycin Resistance Completed NCT01453036 Phase 4
42 Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study. Completed NCT00164866 Phase 4 Omeprazole
43 Helicobacter Pylori Treatment Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
44 Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers Completed NCT00279123 Phase 4 pantoprazole infusion;pantoprazole bolus;no treatment
45 The Studies of the Pathophysiologic Mechanisms of Poor Ulcer Healing & Clinical Improvement to the High Ulcer Rebleeding Rate for Patients With Comorbid Illnesses Completed NCT01591083 Phase 4 esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
46 Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
47 Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot Completed NCT02536989 Phase 4 omeprazole;omeprazole
48 Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction Completed NCT00683111 Phase 4 esomeprazole 20 mg daily;famotidine 40 mg daily
49 Levofloxacin-containing Therapy for Helicobacter Pylori Treatment Completed NCT01667718 Phase 4 Bismuth;Lansoprazole;Levofloxacin;Amoxicillin
50 Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori Completed NCT01667575 Phase 4 Esomeprazole;Amoxicillin;Clarithromycin;Bismuth Potassium Citrate

Search NIH Clinical Center for Peptic Ulcer Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Clidinium bromide
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
methscopolamine bromide
Methscopolamine bromide
methscopolamine nitrate
Propantheline Bromide

Cochrane evidence based reviews: peptic ulcer

Genetic Tests for Peptic Ulcer Disease

Genetic tests related to Peptic Ulcer Disease:

# Genetic test Affiliating Genes
1 Peptic Ulcer 29

Anatomical Context for Peptic Ulcer Disease

MalaCards organs/tissues related to Peptic Ulcer Disease:

Testes, Liver, Colon, Small Intestine, Pancreas, Heart, Kidney

Publications for Peptic Ulcer Disease

Articles related to Peptic Ulcer Disease:

(show top 50) (show all 21494)
# Title Authors PMID Year
Efficacy and safety of Hou Gu Mi Xi for peptic ulcer diseases: Study protocol for a randomized controlled trial. 38 17
31335741 2019
Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. 38 17
31147311 2019
The effect of early Helicobacter pylori eradication on the healing of ESD-induced artificial ulcers: A retrospective study. 17
31145312 2019
In situ expression of cagA and risk of gastroduodenal disease in Helicobacter pylori-infected children. 9 38
20038850 2010
DNA sequence analysis of cagA 3' motifs of Helicobacter pylori strains from patients with peptic ulcer diseases. 9 38
19850704 2010
[Results of evaluating the functional state of the gastric mucosa in duodenal peptic ulcer by means of a test gastropanel in workers engaged in the manufacture of nitrogen compounds]. 9 38
20387669 2010
Diverse characteristics of the CagA gene of Helicobacter pylori strains collected from patients from southern vietnam with gastric cancer and peptic ulcer. 9 38
19846630 2009
Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. 9 38
19930551 2009
[Guidelines of prevention and treatment for NSAID-related peptic ulcers]. 9 38
19934612 2009
Disease association with two Helicobacter pylori duplicate outer membrane protein genes, homB and homA. 9 38
19545429 2009
Detection and evaluation of antibodies against neutrophil-activating protein of Helicobacter pylori in patients with gastric cancer. 9 38
19452583 2009
[Therapeutic and preventive effects of sulfate-chloride-sodium mineral water in experimental peptic ulcer]. 9 38
19639693 2009
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 9 38
18612816 2009
[Genetic features of Helicobacter pylori at patients with duodenal ulcer]. 9 38
20469711 2009
Helicobacter pylori and non-malignant diseases. 9 38
18783518 2008
Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. 9 38
18711705 2008
vacA genotypes of Helicobacter pylori in relation to cagA status and clinical outcomes in Iranian populations. 9 38
18653971 2008
Zollinger-Ellison syndrome: a personal perspective. 9 38
18646472 2008
Differences in virulence markers between Helicobacter pylori strains from Iraq and those from Iran: potential importance of regional differences in H. pylori-associated disease. 9 38
18353934 2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. 9 38
18381949 2008
Prevalence of cagA in relation to clinical presentation of Helicobacter pylori infection in Egypt. 9 38
19086246 2008
Peptic ulceration may be a hormonal deficiency disease. 9 38
18280672 2008
Epidemiology of acute upper gastrointestinal bleeding. 9 38
18346679 2008
Future expectations in the prophylaxis of intestinal bleeding. 9 38
18346690 2008
Preferential induction of transforming growth factor-beta production in gastric epithelial cells and monocytes by Helicobacter pylori soluble proteins. 9 38
17922404 2007
Association between Helicobacter pylori genotypes and gastric disorders in relation to the cag pathogenicity island. 9 38
17521839 2007
Helicobacter pylori cagA and iceA genotypes status and risk of peptic ulcer in Saudi patients. 9 38
17334464 2007
Helicobacter pylori cag pathogenicity island genes: clinical relevance for peptic ulcer disease development in Brazil. 9 38
17172510 2007
Gastrinoma--morphological aspects. 9 38
17985091 2007
Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. 9 38
17088110 2006
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. 9 38
17006979 2006
Association of H pylori cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases. 9 38
16937534 2006
Significance of cagA status and vacA subtypes of Helicobacter pylori in determining gastric histopathology: virulence markers of H. pylori and histopathology. 9 38
16724992 2006
[Microbiologic, serologic diagnosis, and genotypification of Helicobacter pylori isolated from biopsies in children and adult people. Molecular detection of the cag pathogenicity island of Helicobacter pylori]. 9 38
17578080 2006
Clinical and pathological importance of vacA allele heterogeneity and cagA status in peptic ulcer disease in patients from North Brazil. 9 38
16444419 2005
No correlation of babA2 with vacA and cagA genotypes of Helicobacter pylori and grading of gastritis from peptic ulcer disease patients in Brazil. 9 38
16302986 2005
Lower prevalence of Helicobacter pylori infection with vacAs1a, cagA-positive, and babA2-positive genotype in erosive reflux esophagitis disease. 9 38
16302983 2005
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. 9 38
16268979 2005
[BabA2, oipA and cagE Helicobacter pylori genotypes in Colombian patients with gastroduodenal diseases]. 9 38
16276680 2005
Distinct diversity of vacA, cagA, and cagE genes of Helicobacter pylori associated with peptic ulcer in Japan. 9 38
16081930 2005
Clinical Relevance of the vacA, iceA, cagA, and flaA genes of Helicobacter pylori strains isolated in Eastern Taiwan. 9 38
15956417 2005
cagA gene variants in Malaysian Helicobacter pylori strains isolated from patients of different ethnic groups. 9 38
15866222 2005
Distribution of Helicobacter pylori cagA, cagE and vacA in different ethnic groups in Kuala Lumpur, Malaysia. 9 38
15836708 2005
cagA vacA alelles and babA2 genotypes of Helicobacter pylori associated with gastric disease in Brazilian adult patients. 9 38
15808313 2005
Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor. 9 38
15879632 2005
Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. 9 38
15892675 2005
Distribution of vacA alleles and cagA status of Helicobacter pylori in peptic ulcer disease and non-ulcer dyspepsia. 9 38
15606640 2004
Genetic polymorphism of interleukin-8 (IL-8) is associated with Helicobacter pylori-induced duodenal ulcer. 9 38
15627645 2004
Helicobacter pylori density and cagA status in cirrhotic patients: a case-control study. 9 38
15377296 2004
Diversity of vacA and cagA genes of Helicobacter pylori in Japanese children. 9 38
15298599 2004

Variations for Peptic Ulcer Disease

Expression for Peptic Ulcer Disease

Search GEO for disease gene expression data for Peptic Ulcer Disease.

Pathways for Peptic Ulcer Disease

Pathways related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
12.24 TNF S100A8 PTGS2 IL1B CXCL8
Show member pathways
12.18 TNF IL1B IL10 CXCL8
Show member pathways
12.18 TNF PTGS2 IL1B IL10
Show member pathways
12.13 TNF PTGS2 IL1B IL10
Show member pathways
9 12.04 TNF IL1RN IL1B IL10 CXCL8
10 11.95 TNF PTGS2 IL1B CXCL8
Show member pathways
11.92 PTGS2 PTGS1 CYP2C19
12 11.9 PTGS2 PTGS1 CYP2C19
13 11.88 TNF PTGS2 IL1B
14 11.86 TNF IL1B IL10 CXCL8
15 11.85 TNF PTGS2 IL1B CXCL8
16 11.83 TNF IL1B CXCL8
17 11.79 TNF IL1B CXCL8
18 11.78 TNF PTGS2 IL1B IL10 CXCL8
19 11.72 TNF IL1B IL10
Show member pathways
21 11.68 TNF IL1B IL10 CXCL8
22 11.67 TNF IL1B IL10
23 11.59 TNF IL1B CXCL8
Show member pathways
25 11.54 TNF IL1B CXCL8
26 11.4 TNF PTGS2 IL1RN IL1B IL10
27 11.36 TNF IL1B IL10 CXCL8
28 11.32 TNF IL1B IL10
29 11.3 TNF IL1B IL10
30 11.2 TNF IL1B IL10
31 11.13 TNF IL1B IL10 CXCL8
32 10.87 TNF IL1B
33 10.83 PTGS2 PTGS1
34 10.79 TNF PTGS2 IL1RN IL1B IL10 CXCL8
35 10.54 TNF PTGS2 PTGS1 CXCL8
36 10.47 SCT GAST
37 10.13 HRH2 GAST ATP4A

GO Terms for Peptic Ulcer Disease

Cellular components related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNF SCT S100A8 IL1RN IL1B IL10
2 secretory granule lumen GO:0034774 9.43 S100A8 GHRL CAT
3 extracellular space GO:0005615 9.36 TNF SCT S100A8 IL1RN IL1B IL10
4 organelle membrane GO:0031090 9.33 PTGS2 PTGS1 CYP2C19

Biological processes related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.99 TNF IL1RN IL1B IL10 HRH2 CXCL8
2 negative regulation of apoptotic process GO:0043066 9.97 PTGS2 IL10 GHRL CAT
3 regulation of cell proliferation GO:0042127 9.91 TNF PTGS2 PTGS1 GHRL
4 response to lipopolysaccharide GO:0032496 9.91 S100A8 PTGS2 IL1B IL10
5 activation of MAPK activity GO:0000187 9.89 TNF IL1B GHRL
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.87 TNF IL1B IL10
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.87 TNF S100A8 IL1B CAT
8 response to organic substance GO:0010033 9.86 TNF PTGS2 IL10
9 positive regulation of JNK cascade GO:0046330 9.85 TNF IL1RN IL1B
10 cellular oxidant detoxification GO:0098869 9.84 PTGS2 PTGS1 CAT
11 regulation of inflammatory response GO:0050727 9.83 TNF S100A8 PTGS2
12 positive regulation of interleukin-6 production GO:0032755 9.82 TNF IL1RN IL1B
13 cytokine-mediated signaling pathway GO:0019221 9.8 TNF PTGS2 IL1RN IL1B IL10 CXCL8
14 neutrophil chemotaxis GO:0030593 9.78 S100A8 IL1RN IL1B CXCL8
15 cellular response to lipopolysaccharide GO:0071222 9.77 TNF IL1RN IL1B IL10 CXCL8
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.76 TNF PTGS2 IL1B
17 response to fatty acid GO:0070542 9.71 PTGS2 CAT
18 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.71 TNF IL1B
19 positive regulation of glial cell proliferation GO:0060252 9.71 TNF IL1B
20 negative regulation of lipid catabolic process GO:0050995 9.71 TNF IL1B
21 response to ethanol GO:0045471 9.7 S100A8 CAT
22 prostaglandin biosynthetic process GO:0001516 9.7 PTGS2 PTGS1
23 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 TNF IL1B
24 response to drug GO:0042493 9.7 PTGS2 IL10 CAT
25 negative regulation of growth of symbiont in host GO:0044130 9.69 TNF IL10
26 response to estradiol GO:0032355 9.69 PTGS2 CAT
27 response to molecule of bacterial origin GO:0002237 9.68 IL10 CXCL8
28 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.68 IL1RN IL10
29 cyclooxygenase pathway GO:0019371 9.68 PTGS2 PTGS1
30 decidualization GO:0046697 9.67 PTGS2 MEN1 GHRL
31 positive regulation of chemokine biosynthetic process GO:0045080 9.66 TNF IL1B
32 endothelial cell apoptotic process GO:0072577 9.66 TNF IL10
33 regulation of establishment of endothelial barrier GO:1903140 9.65 TNF IL1B
34 positive regulation of neuroinflammatory response GO:0150078 9.64 TNF IL1B
35 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.64 IL10 GHRL
36 negative regulation of cytokine secretion involved in immune response GO:0002740 9.63 TNF IL10
37 embryonic digestive tract development GO:0048566 9.63 TNF SCT CXCL8
38 sequestering of triglyceride GO:0030730 9.6 TNF IL1B
39 response to activity GO:0014823 9.59 IL10 CAT
40 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 TNF IL1B IL10
41 response to inactivity GO:0014854 9.56 IL10 CAT
42 receptor biosynthetic process GO:0032800 9.55 TNF IL10
43 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.54 TNF IL1B
44 memory GO:0007613 9.43 PTGS2 HRH2
45 positive regulation of fever generation GO:0031622 9.43 TNF PTGS2 IL1B
46 ovulation GO:0030728 9.38 PTGS2
47 response to ozone GO:0010193 9.32 CAT
48 response to L-ascorbic acid GO:0033591 9.32 CAT
49 positive regulation of JUN kinase activity GO:0043507 9.27 TNF
50 response to glucocorticoid GO:0051384 9.26 TNF PTGS2 IL1RN IL10

Molecular functions related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.56 PTGS2 PTGS1 CYP2C19 CAT
2 hormone activity GO:0005179 9.54 SCT GHRL GAST
3 peroxidase activity GO:0004601 9.33 PTGS2 PTGS1 CAT
4 interleukin-1 receptor binding GO:0005149 9.32 IL1RN IL1B
5 cytokine activity GO:0005125 9.02 TNF IL1RN IL1B IL10 CXCL8
6 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS2 PTGS1

Sources for Peptic Ulcer Disease

8 C